1,274
Views
20
CrossRef citations to date
0
Altmetric
Original

Evolution of Artificial Cells Using Nanobiotechnology of Hemoglobin Based RBC Blood Substitute as an Example

Pages 551-566 | Published online: 11 Jul 2009

REFERENCES

  • Chang, T.M.S. (1957). “Hb Corpuscles.” Report of a research project for Honours Physiology, Medical Library, McGill University. Also reprinted as part of “30 Anniversary in Artificial Red Blood Cells Research.” J. Biomaterials, Artificial Cells & Artificial Organs 16: 1–9. [INFOTRIEVE]
  • Chang, T.M.S. (1964). Semipermeable microcapsules. Science 146(3643): 524. [INFOTRIEVE], [CSA], [CROSSREF]
  • Chang, T.M.S. (1965). Ph.D. Thesis, McGill University.
  • Chang, T.M.S. (1972). Artificial cells. Monograph. Charles C. Thomas, Springfield, IL (full text available for free online viewing at www.artcell.mcgill.ca).
  • Chang, T.M.S. (1975). Microencapsulated adsorbent hemoperfusion for uremia, intoxication and hepatic failure. Kidney Int. 7: S387–S392. [CSA]
  • Winchester, J.F. (1988). Hemoperfusion, in Replacement of Renal Function by Dialysis, J.F. Maher, Ed., Kluwer Academic Publisher: Boston, pp. 439–592.
  • Chang, T.M.S. (1976). Biodegradable semipermeable microcapsules containing enzymes, hormones,vaccines, and other biologicals. J. Bioengineering 1: 25–32. [CSA]
  • Chang, T.M.S. (1991). Artificial cells, in Encyclopedia of Human Biology, Renalo Dulbecco, Ed., Volume 1, Academic Press, Inc.: San Diego, CA, pp. 377–383.
  • Chang, T.M.S. (2005). Therapeutic applications of polymeric artificial cells. Nature Review: Drug Discovery 4: 221–235. [CSA], [CROSSREF]
  • Liu, Z.C., Chang, T.M.S. (2006). Transdifferentiation of bioencapsulated bone marrow cells into hepatocyte-like cells in the 90% hepatectomized rat model. Journal of Liver Transplantation 12: 566–572. [CSA], [CROSSREF]
  • Orive, G., Hernandez, R.M., Gascon, A.R., Calafiore, R., Chang, T.M.S. et al. (2003). Cell encapsulation: promise and progress. Nature Medicine 9: 104–107. [INFOTRIEVE], [CSA], [CROSSREF]
  • Chang, T.M.S. (2006). Blood substitutes based on bionanotechnology. Trends in Biotechnology 24: 72–377. [CSA], [CROSSREF]
  • Chang, T.M.S. (1971). Stabilization of enzyme by microencapsulation with a concentrated protein solution or by crosslinking with glutaraldehyde. Biochem Biophys. Res Com. 44: 1531–1533. [INFOTRIEVE], [CSA], [CROSSREF]
  • Gould, S.A., Sehgal, L.R., Sehgal, H.L., DeWoskin, R., Moss, G.S. (1998). The clinical development of human polymerized Hb, in Blood Substitutes: Principles, Methods, Products and Clinical Trials, T.M.S. Chang, Ed., Vol. 2, Karger, pp. 12–28.
  • Gould, S.A. , et al (2002). The life-sustaining capacity of human polymerized Hb when red cells might be unavailable. J. Am. Coll. Surg. 195: 445–452. [INFOTRIEVE], [CSA], [CROSSREF]
  • Sprung, J., Kindscher, J.D., Wahr, J.A., Levy, J.H., Monk, T.G., Moritz, M.W., O'Hara, P.J. (2002). The use of bovine Hb glutamer-250 (Hemopure) in surgical patients: Results of a multicenter, randomized, single-blinded trial. Anesth Analg 94(4): 799–808. [INFOTRIEVE], [CSA], [CROSSREF]
  • Pearce, L.B., Gawryl, M.S., Rentko, V.T., Moon-Massat, P.F., Rausch, C.W. (2006). HBOC-201 (Hb Glutamer-250 (bovine), hemopure): clinical studies, in Blood Substitutes, R. Winslow, Ed., Academic Press: San Diego, pp. 437–450.
  • Lok, C. (2001). Blood product from cattle wins approval for use in humans. Nature 410(6831): 855. [INFOTRIEVE], [CSA], [CROSSREF]
  • Li, T., Yu, R., Zhang, H.H., Liang, W.G., Yang, X.M., Yang, C.M. (2006). A method for purification and viral inactivation of human placenta Hb. Artificial Cells, Blood Substitutes and Biotechnology 34: 175–188. [CSA], [CROSSREF]
  • Wong, J.T. (1988). Rightshifted dextran Hb as blood substitute. Biomaterials, Artificial Cells and Artificial Organs 16: 237–245. [CSA]
  • Shorr, R.G., Viau, A.T., Abuchowski, A. (1996). Phase 1B safety evaluation of PEG Hb as an adjuvant to radiation therapy in human cancer patients. Artficial Cells, Blood Substitutes and Immobilization Biotechnology 24: 407. [CSA]
  • Iwashita, Y., Yabuki, A., Yamaji, K., Iwasaki, K., Okami, T., Hirati, C., Kosaka, K. (1988). A new resuscitation fluid “Stabilized Hb” preparation and characteristics. Biomaterials, Artificial Cells and Artificial Organs 16: 271–280. [CSA]
  • Winslow, R. (2006). Blood Substitutes, Academic Press: San Diego.
  • Nelson, D.J. (1998). Blood and HemAssistTM (DCLHb): Potentially a complementary therapeutic team, in Blood Substitutes: Principles, Methods, Products and Clinical Trials, T.M.S. Chang, Ed., Vol. 2, Karger: Basel, pp. 39–57.
  • Burhop, K.E., Estep, T.E. (2001). Hb induced myocardial lesions. Artf. Cells Blood Subst. Immob Biotech. 29: 101–106. [CSA]
  • Fronticelli, C., Bellelli, A., Briniger, W.S. (2004). Approach to the engineering of Hb based oxygen carrier. Transfusion Mediciner 5: 516–520. [CSA]
  • Olsen, J.S., Foley, E.W., Rogge, C. (2004). Nitric oxide scavenging and the hypertensive effect of Hb-based blood substitutes. Free Radic. Biol. Med. 36: 685–697. [CSA], [CROSSREF]
  • Alayash, A.I. (2004). Oxygen therapeutics: Can we tame Hb. Nature Rev. Drug Discov. 3: 152–159. [CSA], [CROSSREF]
  • Chang, T.M.S. (1997). Blood Substitutes: Principles, Methods, Products and Clinical Trials. Vol. 1, Karger, Basel (full text available for free online viewing at www.artcell.mcgill.ca).
  • De Angelo, J. (1999). Nitric oxide scavengers in the treatment of shock associated with systemic inflammatory response syndrome. Exp. Opin. Pharmacother 1: 19–29. [CSA], [CROSSREF]
  • Doherty, D.H., Doyle, M.P., Curry, S.R., Vali, R.J., Fattor, T.J., Olson, J.S., Lemon, D.D. (1998). Rate of reaction with nitric oxide determines the hypertensive effect of cell-free Hb. Nature Biotechnology 16: 672–676. [INFOTRIEVE], [CSA], [CROSSREF]
  • Matheson, B., Kwansa, H.E., Rebel, A., Bucci, E. (2002). Vascular responses to infusions of a non-extravasating Hb polymer. J. Appl. Physiol. 93: 1479–1486. [INFOTRIEVE], [CSA]
  • Tsai, A., Vandegriff, K., Intaglietaa, M., Winslow, R. (2003). Targeted oxygen delivery by cell-free Hb: a new basis for oxtgen therapeutics. Am. J. Physiol. 285: H1411–H1419. [CSA]
  • Yu, B.L., Liu, Z.C., Chang, T.M.S. (2006). PolyHb with different percentage of tetrameric Hb and effects on vasoactivity and electrocardiogram. Artificial Cells, Blood Substitutes & Biotechnology 34: 159–174. [INFOTRIEVE], [CSA], [CROSSREF]
  • D'Agnillo, F., Chang, T.M.S. (1998). PolyHb-superoxide dismutase. Catalase as a blood substitute with antioxidant properties. Nature Biotechnology 16(7): 667–671. [INFOTRIEVE], [CSA], [CROSSREF]
  • Chang, T.M.S., D'Agnillo, F., Razack, S. (1998). A second generation Hb based blood substitute with antioxidant activities, in Blood Substitutes: Principles, Methods, Products and Clinical Trials, T.M.S. Chang, Ed., Karger: Basel, Vol. 2, pp. 178–186.
  • Powanda, D., Chang, T.M.S. (2002). Cross-linked polyHb-superoxide dismutase-catalase supplies oxygen without causing blood brain barrier disruption or brain edema in a rat model of transient global brain ischemia-reperfusion. Artificial Cells, Blood Substitutes & Immob. Biotechnology 30: 25–42. [INFOTRIEVE], [CSA]
  • Buehler, P.W., Mehendale, S., Wang, H., Xie, J., Ma, L., Trimble, C.E., Hsia, C.J., Gulati, A. (2000). Resuscitative effects of polynitroxylated alpha-alpha-cross-linked Hb following severe hemorrhage in the rat. Free Radic Biol Med. 29(8): 764–774. [INFOTRIEVE], [CSA], [CROSSREF]
  • Yu, B.L., Chang, T.M.S. (2004). In vitro and in vivo effects of polyHb–tyrosinase on murine B16F10 melanoma. Melanoma Res. 14: 197–202. [INFOTRIEVE], [CSA], [CROSSREF]
  • Chang, T.M.S., Poznansky, M.J. (1968). Semipermeable microcapsules containing catalase for enzyme replacement in acatalsaemic mice. Nature 218(5138): 242–245. [CSA], [CROSSREF]
  • Rudolph, A.S., Rabinovici, R., Feuerstein, G.Z. (1997). Red Blood Cell Substitutes: Basic Principles and Clinical Applications, Marcel Dekker, Inc.: New York.
  • Philips, W.T., Klepper, R.W., Awasthi, V.D., Rudolph, A.S., Cliff, R., Kwasiborski, V.V., Goins, B.A. (1999). Polyethylene glyco-modified liposome-encapsulated Hb: a long circulating red cell substitute. J. Pharm. Exp. Therapeutics 288: 665–670. [CSA]
  • Tsuchida, E., Komatsu, T., Yanagimoto, T., Sakai, H. (2002). Preservation stability and in vivo administration of albumin-heme hydrid solution as an entirely synthetic oxygen-carrier. Polymer Adv. Technol. 13: 845–850. [CSA], [CROSSREF]
  • Kobayashi, K., Tsuchida, E., Horinouchi, H. (2005). Artificial Oxygen Carriers, Springer Verlag: New York.
  • Yu, W.P., Chang, T.M.S. (1996). Submicron polymer membrane Hb nanocapsules as potential blood substitutes: preparation and characterization. Artificial Cells, Blood Substitutes & Immobilization Biotechnology 24: 169–184. [INFOTRIEVE], [CSA]
  • Chang, T.M.S., Yu, W.P. (1998). Nanoencapsulation of Hb and rbc enzymes based on nanotechnology and biodegradable polymer, in Blood Substitutes: Principles, Methods, Products and Clinical Trials, T.M.S. Chang, Ed., Karger: Basel, Vol. 2, pp. 216–231.
  • Chang, T.M.S., Powanda, D., Yu, W.P. (2003). Ultrathin polyethylene-glycol-polylactide copolymer membrane nanocapsules containing polymerized Hb and enzymes as nano-dimension red blood cell substitutes. Artificial Cells, Blood Substitutes & Biotechnology 31(3): 231–248. [INFOTRIEVE], [CSA], [CROSSREF]

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.